- Home
- RPRX vs LBRDK Comparison
RPRX vs LBRDK Comparison
Compare RPRX & LBRDK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- LBRDK
- Stock Information
- Founded
- RPRX 1996
- LBRDK 2014
- Country
- RPRX United States
- LBRDK United States
- Employees
- RPRX N/A
- LBRDK N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- LBRDK Cable & Other Pay Television Services
- Sector
- RPRX Health Care
- LBRDK Telecommunications
- Exchange
- RPRX Nasdaq
- LBRDK Nasdaq
- Market Cap
- RPRX 13.9B
- LBRDK 12.1B
- IPO Year
- RPRX 2020
- LBRDK N/A
- Fundamental
- Price
- RPRX $36.03
- LBRDK $96.93
- Analyst Decision
- RPRX Strong Buy
- LBRDK Buy
- Analyst Count
- RPRX 3
- LBRDK 2
- Target Price
- RPRX $47.33
- LBRDK $80.00
- AVG Volume (30 Days)
- RPRX 4.3M
- LBRDK 1.5M
- Earning Date
- RPRX 08-07-2025
- LBRDK 08-07-2025
- Dividend Yield
- RPRX 2.44%
- LBRDK N/A
- EPS Growth
- RPRX 37.60
- LBRDK 6.21
- EPS
- RPRX 2.45
- LBRDK 6.26
- Revenue
- RPRX $2,263,845,000.00
- LBRDK $1,037,000,000.00
- Revenue This Year
- RPRX $29.35
- LBRDK $5.22
- Revenue Next Year
- RPRX $7.58
- LBRDK $2.34
- P/E Ratio
- RPRX $14.72
- LBRDK $15.52
- Revenue Growth
- RPRX 1.13
- LBRDK 5.82
- 52 Week Low
- RPRX $24.05
- LBRDK $51.97
- 52 Week High
- RPRX $36.32
- LBRDK $104.00
- Technical
- Relative Strength Index (RSI)
- RPRX 64.81
- LBRDK 57.41
- Support Level
- RPRX $35.01
- LBRDK $92.41
- Resistance Level
- RPRX $36.14
- LBRDK $96.17
- Average True Range (ATR)
- RPRX 0.70
- LBRDK 2.46
- MACD
- RPRX 0.10
- LBRDK 0.14
- Stochastic Oscillator
- RPRX 90.07
- LBRDK 90.66
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About LBRDK Liberty Broadband Corporation Class C
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.